Moreover, we demonstrated that IL-33 has an inhibitory effect on IL-25-mediated IL-17A expression in hepatic ILC2, indicating that in IL-33-triggered liver diseases, the development of inflammatory ILC2 might be suppressed. This evidence concerns the gene IL17A and liver disorder.